Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Kenji Sakuma"'
Publikováno v:
Neuropsychopharmacology Reports, Vol 44, Iss 1, Pp 165-175 (2024)
Abstract Aim This systematic review and frequentist network meta‐analysis used random‐effects models is conducted to determine whether there are differences in the efficacy, acceptability, tolerability, and safety profiles of brexpiprazole (BRE)
Externí odkaz:
https://doaj.org/article/295d7df1367c46ba8da15b0a8269c872
Autor:
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata
Publikováno v:
Neuropsychopharmacology Reports, Vol 44, Iss 1, Pp 267-271 (2024)
Abstract Aim To update the major depressive disorder (MDD) treatment guidelines of the Japanese Society of Mood Disorders, we conducted a systematic review and pairwise meta‐analysis of double‐blind, randomized, placebo‐controlled trials of ava
Externí odkaz:
https://doaj.org/article/473c75bb15464286a3387b7057e954ba
Autor:
Taro Kishi, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, Satoru Esumi, Nobumi Miyake, Itaru Miura, Hikaru Hori, Masaki Kato, Nakao Iwata
Publikováno v:
Neuropsychopharmacology Reports, Vol 44, Iss 1, Pp 216-220 (2024)
Abstract Introduction The question remains to be elucidated: “Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?” It is crucial to confirm this in order to provide appropriate treatments for Jap
Externí odkaz:
https://doaj.org/article/7bd9cab4e4ec4052919a8dd7b78746e1
Autor:
Yuki Matsuda, Kenji Sakuma, Taro Kishi, Kosei Esaki, Shinsuke Kito, Masahiro Shigeta, Nakao Iwata
Publikováno v:
Brain Stimulation, Vol 16, Iss 2, Pp 458-461 (2023)
Externí odkaz:
https://doaj.org/article/74014ec47f9745418cdd3b07a13819e3
Publikováno v:
Translational Psychiatry, Vol 12, Iss 1, Pp 1-6 (2022)
Abstract Is paliperidone palmitate (PP) a useful treatment option for adults with acute symptoms of schizophrenia? We conducted a systematic review and a random-effects pairwise and network meta-analysis that compared PP (25−150 mg equivalent) with
Externí odkaz:
https://doaj.org/article/d101a7b800da4ccd9c609baa5c29ce57
Publikováno v:
Translational Psychiatry, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract It remains unclear whether mitochondrial modulators (MMs) are beneficial in the treatment of obsessive–compulsive and related disorders. Thus, in an attempt to answer this clinical question, we performed a systematic review and a random-ef
Externí odkaz:
https://doaj.org/article/28ebf9b84ad443aeafe6c3e402be2b77
Autor:
Taro Kishi, Maika Nishida, Michinori Koebis, Takehiro Taninaga, Kenzo Muramoto, Naoki Kubota, Margaret Moline, Kenji Sakuma, Makoto Okuya, Ikuo Nomura, Nakao Iwata
Publikováno v:
Neuropsychopharmacology Reports, Vol 41, Iss 4, Pp 450-458 (2021)
Abstract Most conventional insomnia medications are gamma‐aminobutylic acid receptor agonists. However, physical dependence is a concern and one of the major limiting factors for long‐term treatment. The dual orexin receptor antagonists, suvorexa
Externí odkaz:
https://doaj.org/article/e1c3cd06cd9f45a8a585f4644d879cd0
Publikováno v:
PCN Reports, Vol 1, Iss 4, Pp n/a-n/a (2022)
Externí odkaz:
https://doaj.org/article/863450322a91450bb050b06414b2ef5b
Publikováno v:
Neuropsychopharmacology Reports, Vol 41, Iss 3, Pp 422-425 (2021)
Abstract Aim We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long‐acting injectable second‐generation antipsychotic (LAI‐SGA) therapy due to adverse events (AEs). Methods The stud
Externí odkaz:
https://doaj.org/article/135e86fee2ed4c6998c4a43e588cf70f
Publikováno v:
PCN Reports, Vol 1, Iss 3, Pp n/a-n/a (2022)
Externí odkaz:
https://doaj.org/article/4e8809a0e7324010b7a6522b3814f40d